ICU Review

Use of Sodium–Glucose Cotransporter 2 Inhibitors in Hospitalized Patients: Administration approved the following: 1) in 2016, empagliflozin to reduce the risk of CV death in adults with T2D and established CV disease ✅ 2) in September 2019, canagliflozin to treat diabetic kidney disease ✅ 3) in May 2020, dapagliflozin for HFrEF ✅ 4) in May 2021, dapagliflozin to treat patients with CKD at risk of disease progression, regardless of diabetes and albuminuria status 👆✅ and 5) in September 2022, empagliflozin for HFpEF 🔶 and September 2023, empagliflozin for CKD without DM or HF.

Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: A narrative review

Treatment of OSA and its impact on Cardiovascular Disease, Part 2.pdf

Therapeutic Approach to Autoimmune Neurologic Disorders.pdf

Community-Acquired Pneumonia A Review.pdf

Autoimmune Encephalitis.pdf

Overview and Diagnostic Approach in Autoimmune Neurology.pdf

Obstructive sleep apnea, cognitive impairment, and dementia is sleep microstructure an important feature.pdf

Lipoprotein(a) and cardiovascular disease.pdf

Genetically predicted hypothyroidism, thyroid hormone treatment, and the risk of cardiovascular diseases a mendelian randomization study.pdf